Typewriter Therapeutics has filed a notice of an exempt offering of securities to raise $56,299,999.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Typewriter Therapeutics is raising up to $56,299,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Typewriter Therapeutics
Typewriter Therapeutics is a biotechnology company developing all-RNA genetic medicines for people with cancer, autoimmune diseases, severe genetic diseases, and other life-threatening conditions. Its platform uses lipid nanoparticle-delivered RNA to insert full-length therapeutic genes into a natural genomic safe-harbor site without viral vectors or double-strand DNA breaks. The company is initially pursuing in vivo engineered CAR-T cells and gene insertion into the liver to treat severe rare diseases. Typewriters technology is based on R2 retrotransposons and is designed to provide precise, non-viral, durable, and potentially re-dosable gene insertion. Operating across Cambridge, Massachusetts, and Tokyo, Japan, the company describes itself as an emerging developer of a new category of genetic medicines. On September 2, 2026, Typewriter announced that it had emerged from stealth with a $56 million Series A financing to support its pursuit of in vivo CAR-T medicines.

To learn more, visit https://typewritertx.com/
LinkedIn: https://www.linkedin.com/company/typewritertx/

Contact:
Matthew Stanton, Chief Executive Officer
https://www.linkedin.com/in/matthew-g-stanton/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.